8HTS image
Entry Detail
PDB ID:
8HTS
Keywords:
Title:
Crystal structure of Bcl2 in complex with S-10r
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2022-12-21
Release Date:
2024-05-15
Method Details:
Experimental Method:
Resolution:
1.25 Å
R-Value Free:
0.18
R-Value Work:
0.16
R-Value Observed:
0.16
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Apoptosis regulator Bcl-2
Chain IDs:A
Chain Length:171
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2.
J.Med.Chem. 67 7836 7858 (2024)
PMID: 38695063 DOI: 10.1021/acs.jmedchem.4c00027

Abstact

The approval of venetoclax, a B-cell lymphoma-2 (Bcl-2) selective inhibitor, for the treatment of chronic lymphocytic leukemia demonstrated that the antiapoptotic protein Bcl-2 is a druggable target for B-cell malignancies. However, venetoclax's limited potency cannot produce a strong, durable clinical benefit in other Bcl-2-mediated malignancies (e.g., diffuse large B-cell lymphomas) and multiple recurrent Bcl-2 mutations (e.g., G101V) have been reported to mediate resistance to venetoclax after long-term treatment. Herein, we described novel Bcl-2 inhibitors with increased potency for both wild-type (WT) and mutant Bcl-2. Comprehensive structure optimization led to the clinical candidate BGB-11417 (compound 12e, sonrotoclax), which exhibits strong in vitro and in vivo inhibitory activity against both WT Bcl-2 and the G101V mutant, as well as excellent selectivity over Bcl-xL without obvious cytochrome P450 inhibition. Currently, BGB-11417 is undergoing phase II/III clinical assessments as monotherapy and combination treatment.

Legend

Protein

Chemical

Disease

Primary Citation of related structures